Laboratory Corp of America LH

$328.95 -0.98 (-0.30%)

Valuation

Market cap
26,757,320,000
Revenue TTM
$13,951,700,000
Net income TTM
$876,500,000
PE ratio
18.51
Forward PE
17.67
Profit margin
6.28%
Debt to equity
0.68

Trading

Volume
663,900
Avg volume
714,768
Day's range
$326.83 – $331.57
Shares out
81,100,000
Stochastic %K
86%
Beta
0.87
Analysts
Strong Sell
Price target
$349.06

Price

Company profile

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse te...

Show more

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Industry
Diagnostics & Research
Sector
Healthcare
Website
https://www.labcorp.com
Address
531 South Spring Street, Burlington, United States

Latest news

Stocktwits

thatsolardude365 Oct 23, 8:43 PM
$LH: three objections were overruled when a judge gave final approval Aug 20 to the $35M Labcorp AMCA settlement. Filed claimants now wait for it to become effective before payments. Open Class Actions.
0 replies
thatsolardude365 Oct 22, 11:17 AM
$LH: Labcorp AMCA claimants could elect 2 years of CyEx Medical Shield Pro monitoring on top of their cash choice. Cash is about $50 no-proof or up to $5,000 documented, both pro rata. Claims closed. Open Class Actions.
0 replies
Rayvio_News_Filter Oct 21, 6:35 PM
$OPK · $LH 🤝 OPKO Health, Inc. agrees to sell select BioReference Health, LLC assets to Labcorp for $722 million in cash at closing, plus up to $150 million earnout tied to 4Kscore Test revenue, subject to regulatory approvals.
1 replies
KryptonResearch14 Oct 21, 7:03 AM
$MYGN Selling the prenatal business to $LH for 210 million dollars in cash, plus inventory at closing. The stock closed up 31.6% Tuesday, and the math kinda explains it, that cash is roughly 52% of what the whole company was worth at Monday's close. Prenatal was the shrinking piece anyway. Q2 revenue fell 16% to 39.8 million dollars on 9% lower volume, and Labcorp expects about 160 million dollars of revenue from the business in its first year, so Myriad is getting roughly 1.3x sales for a segment that was shrinking.
0 replies
topstockalerts Oct 20, 4:20 PM
Myriad Genetics agreed to sell its prenatal testing business to Labcorp for $210 million in cash plus inventory value at closing. The deal includes the Prequel, Foresight, SneakPeek, and FirstGene tests, which generated approximately $160 million in revenue over the past 12 months and served more than 600,000 patients, implying a purchase price of roughly 1.3x trailing revenue, excluding inventory. Myriad CEO Sam Raha said the divestiture should support revenue growth and profitability while strengthening the balance sheet to fund strategic investments in oncology care. Labcorp expects the acquisition to add approximately $160 million in first-year revenue and modestly increase adjusted earnings. It aims to reach its Diagnostics segment’s average margins by the end of the second year, following integration. The transaction remains subject to regulatory approval and customary closing conditions, with completion expected in early 2027. $MYGN $LH
0 replies
prismmarketview Oct 20, 3:17 PM
$MYGN to sell its Prenatal Health business to Labcorp $LH for $210M cash plus inventory → Includes Prequel, Foresight, SneakPeek, FirstGene → Labcorp projects ~$160M first-year revenue, slightly accretive to adjusted EPS → Closing expected by early 2027 (regulatory clearance needed) → Myriad Q3 call: Nov. 4 Caveats: not yet closed. Labcorp figures are projections. No Myriad financial guidance changes disclosed. $MYGN #Diagnostics https://prismmarketview.com/myriad-genetics-to-sell-prenatal-testing-business-to-labcorp-for-210-million/
0 replies
notreload_ai Oct 20, 1:26 PM
$MYGN agrees to sell its Prenatal Health testing business, including Prequel and Foresight, to $LH for $210 million, closing by early 2027. https://notreload.xyz/xy/myriad-sells-prenatal-tests-to-labcorp-for-210m/
0 replies
Rayvio_News_Filter Oct 20, 12:32 PM
$MYGN · $LH 🤝 Myriad Genetics, Inc. agrees to sell its Prenatal Health testing business, including Prequel, Foresight, SneakPeek, and FirstGene tests, to Laboratory Corporation of America Holdings for $210 million in cash plus the value of inventory at closing, to support Myriad’s strategic priorities and expand patient access. Actionable market event
0 replies